Navigation Links
Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech
Date:10/6/2009

NEW YORK, Oct. 6 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue.

Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech

http://www.reportlinker.com/p0151441/Reportlinker-Adds-Drug-Delivery-Partnering-Agreements-in-Pharma-and-Biotech.html

Description

The Drug Delivery Partnering Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the drug delivery partnering agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors drug delivery technology or drug delivery-enabled product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains over 800 links to online copies of actual drug delivery contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of drug delivery dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of drug delivery dealmaking since 2000. The chapter includes numerous case studies to enable understanding of diagnostic dealmaking. Chapter 3 provides an overview of the trends in drug delivery dealmaking since 2000. Chapter 4 provides a review of the leading drug delivery deals since 2003. Deals are listed by headline value, signed by bigpharma, most active bigpharma, most active drug delivery companies, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive listing of the leading 35 drug delivery companies with a brief summary followed by a comprehensive listing of drug delivery contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 7 provides a comprehensive and detailed review of drug delivery partnering deals signed and announced since 2003, where a contract document is available in the public domain. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in drug delivery partnering and dealmaking since 2000.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of drug delivery technologies and products.

Key benefits

Drug Delivery Partnering Agreements in Pharma and Biotech provides the reader with the following key benefits:

In-depth understanding of drug delivery deal trends since 2000

Analysis of the structure of drug delivery agreements with numerous real life case studies

Comprehensive access to over 800 actual drug delivery contracts entered into by the world's biopharma companies

Detailed access to actual drug delivery contracts enter into by the leading fifty bigpharma companies

Insight into the terms included in a drug delivery agreement, together with real world clause examples

Understand the key deal terms companies have agreed in previous deals

Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Drug Delivery Partnering Agreements in Pharma and Biotech is intended to provide the reader with an in-depth understanding of the drug delivery trends and structure of deals entered into by leading companies worldwide.

Drug Delivery Partnering Agreements in Pharma and Biotech includes:

Trends in drug delivery dealmaking in the biopharma industry since 2000

Analysis of drug delivery deal structure

Case studies of real-life drug delivery deals

Access to over 800 drug delivery contract documents

The leading drug delivery deals by value since 2000

Most active drug delivery dealmakers since 2000

The leading drug delivery partnering resources

In Drug Delivery Partnering Agreements in Pharma and Biotech, the available contracts are listed by:

Company A-Z

Headline value

Stage of development at signing

Deal component type

Specific therapy target

Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Overview of drug delivery dealmaking

2.1. Introduction

2.2. The anatomy of drug delivery partnering

2.3. Drug delivery or specialty pharma?

2.3.1. Is specialty pharma the only way for drug delivery?

2.3.2. Best practice for optimizing drug delivery program development

2.2.3. The anatomy of a drug delivery deal

2.2.3.a. Case study 1: Alpharma - Durect - September 2008

2.2.3.b. Case study 2: Bayer - MDRNA - August 2007

2.2.3.c. Case study 3: Aradigm - Lung Rx - August 2007

Chapter 3 - Trends in drug delivery dealmaking

3.1. Introduction

3.2. Drug delivery partnering since 2000

3.3. Most active drug delivery dealmakers

3.4. Bigpharma drug delivery dealmaking activity

3.5. Bigpharma not active in drug delivery

3.6. Drug delivery partnering by deal type

3.6.1. Option and evaluation drug delivery partnering

3.7. Drug delivery partnering by disease type

3.8. Drug delivery M&A activity since 2000

Chapter 4 - Leading drug delivery deals

4.1. Introduction

4.2. Top drug delivery deals by value

4.3. Top drug delivery involving bigpharma

4.4. Leading drug delivery M&A deals by value

Chapter 5 - Bigpharma drug delivery deals

5.1. Introduction

5.2. How to use bigpharma drug delivery partnering deals

5.3. Bigpharma partnering company profiles

Actavis

Alcon Labs

Allergan

Astellas

AstraZeneca

Baxter International

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Cephalon

Daiichi Sankyo

Dainippon Sumitomo

Eli Lilly

Forest Laboratories

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

Hospira

Johnson & Johnson

Lundbeck

Menarini

Merck & Co

Merck - Serono

Mitsubishi Tanabe

Novartis

Novo Nordisk

Nycomed Pharma

Procter & Gamble

Ratiopharm

Sanofi-Aventis

Schering Plough

Servier

Chapter 6 - Drug delivery company deals

5.1. Introduction

5.2. How to use drug delivery company partnering deals

5.3. Drug delivery partnering company profiles

3M Drug Delivery Systems

Alkermes

Altea Pharmaceuticals

Aradigm

Bioject

Biovail

Cardinal Health

Cima Labs

Connetics

Cydex Pharmaceuticals

Depomed

Dor Biopharma

Emisphere

Ethypharm

Generex

Inovio (formerly Genetronics)

Macrochem

Macromed

MDRNA (formerly Nastech)

Penwest

Pherin Pharmaceuticals

Psivida

Skyepharma

Watson Pharmaceuticals

Zogenix

Chapter 7 - Drug delivery dealmaking directory

7.1. Introduction

7.2. Company A-Z

7.3. By stage of development

Discovery

Pre-clinical

Phase I

Phase II

Phase III

Registration

Marketed

7.4. By deal type

Asset and product purchase

Collaborative R&D

Co-development

Co-marketing

Co-promotion

Development

Distribution

Joint venture

Licensing

M&A

Manufacturing

Marketing

Promotion

Research

7.5. By therapy area

Cardiovascular

Central nervous system

Dermatology

Gastrointestinal

Genitourinary

Hematology

Immunology

Infection

Inflammation

Metabolic

Musculoskeletal

Oncology

Ophthalmics

Respiratory

Animal health

Chapter 8 - Drug delivery partnering resource center

8.1. Online drug delivery partnering

8.2. Drug delivery partnering events

8.3. Further reading on drug delivery dealmaking

Appendices

Appendix 1 - Deal type definitions

Appendix 2 - Example drug delivery partnering agreement

About CurrentPartnering

Recent titles from CurrentPartnering

Figures in report

Figure 1: Components of the typical drug delivery deal structure

Figure 2: Best practice for drug delivery program development

Figure 3: Drug delivery partnering since 2000

Figure 4: Most active drug delivery dealmakers 2003-2008

Figure 5: Most active bigpharma signing drug delivery deals 2003-2008

Figure 6: Bigpharma - top 50 - drug delivery deals 2003 to 2008

Figure 7: Inactive bigpharma in drug delivery dealmaking 2003-2008

Figure 8: Drug delivery partnering by deal type since 2003

Figure 9: Drug delivery option deals since 2003

Figure 10: Drug delivery partnering by disease type from 2003

Figure 11: Drug delivery M&A since 2000

Figure 12: Top drug delivery deals by value since 2000

Figure 13: Top drug delivery deals signed by bigpharma value since 2000

Figure 14: Top drug delivery M&A deals by value since 2000

Figure 15: Online partnering resources

Figure 16: Forthcoming partnering events

Figure 17: Deal type definitions

Figure 18: Drug delivery partnering agreement between Solvay and Depomed, November 2008

To order this report:

Reportlinker Adds Drug Delivery Partnering Agreements in Pharma and Biotech

http://www.reportlinker.com/p0151441/Reportlinker-Adds-Drug-Delivery-Partnering-Agreements-in-Pharma-and-Biotech.html

More market research reports here!

    CONTACT:
    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds US Disposable Medical Supplies Market Report
2. Reportlinker Adds Gilead Sciences Inc.: PharmaVitae Profile
3. CellCyte Genetics Corp. Enters Collaborative Research Agreement With Cleveland Clinic Foundation to Qualify Stem Cell Delivery in Damaged Heart Tissue
4. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
5. Study Shows Intradigms RNAi Nanoplex Technology To Be Effective Systemic siRNA Delivery Platform for the Treatment of Various Cancer Models
6. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
7. Halozyme Therapeutics Presents Pre-Clinical Studies of Systemic Delivery of Pegylated rHuPH20 Enyzme in Prostate Cancer Models at American Association for Cancer Research Conference
8. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
9. Phosphagenics Reports Positive Pre-clinical Results for Targeted Delivery of Lidocaine
10. TARGETED GENE DELIVERY IN VIVO: Rexin-G Monotherapy Reveals Significant Biological Activity Without Toxicity in Chemo-Resistant Metastatic Breast Cancer (ASCO 2008)
11. TARGETED GENE DELIVERY SIGNALS CANCER VACCINATION IN VIVO: Intravenous Infusions of Rexin-G Followed by Reximmune-C Induce Tumor Necrosis and Recruitment of Tumor Infiltrating Lymphocytes in Cancerous Lesions (ASCO 2008)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... , June 23, 2016 Roche (SIX: RO, ... clearance for its Elecsys BRAHMS PCT (procalcitonin) assay as ... or septic shock. With this clearance, Roche is the ... fully integrated solution for sepsis risk assessment and management. ... bacterial infection and PCT levels in blood can aid ...
(Date:6/23/2016)... 2016 , , , WHEN: ... 2016 , , , , LOCATION: , , , Online, ... , , EXPERT PANELISTS:  , , , Frost & Sullivan,s Global ... Bird; Senior Industry Analyst, Divyaa Ravishankar and Unmesh Lal, Program Manager ... pharmaceutical industry is witnessing an exceptional era. Several new demand spaces, ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever Recovery, a ... and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation facility is ... to some of the world’s leading providers of cereal and other breakfast foods. Its ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts ... applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention ... health care topics including advance care planning, healthcare costs and patient and family ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar ... M.D from the David Geffen School of Medicine at UCLA. He trained in Internal ... complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had ...
(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... To deal with these feelings, many turn to unhealthy avenues, such as drug or ... Center of Marne, Michigan, has released tools for healthy coping following a traumatic event. ...
Breaking Medicine News(10 mins):